

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

October 27, 2026

To The Manager, Listing Department National Stock Exchange of India Limited Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
--	--

Sub.: Outcome of Board Meeting held today i.e. Tuesday, October 27, 2026 - Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") as amended from time to time.

Dear Sir/ Ma'am,

With reference to the intimation of Board meeting submitted on October 22, 2026, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Tuesday, October 27, 2026, has inter-alia considered and approved the following:

1. UN-AUDITED FINANCIAL RESULTS

On review and recommendation of Audit Committee of the Company, has inter-alia considered and approved, the unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended on September 30, 2026.

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the unaudited Standalone and Consolidated Financial Results of the Company for the second quarter and half year ended on September 30, 2026, along with the Limited Review Reports issued by M/s. BSR & Co. LLP, the Statutory Auditors.

2. RECORD DATE FOR ISSUE OF BONUS EQUITY SHARES

With reference to the intimation of outcome of Board meeting dated September 23, 2026, the Board has fixed Wednesday, November 04, 2026 as record date for the purpose of identifying the shareholders to whom Bonus Equity shares shall be allotted. The Company shall also make a separate disclosure in this regard to the Stock Exchange.

3. RECONSTITUTION OF COMMITTEES OF BOARD

Pursuant to Regulation 30 read with Regulations 18, 19, & 21 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors has reconstituted the Audit Committee, Nomination and Remuneration Committee, Risk Management Committee and Corporate Social Responsibility Committee of the Company. The revised composition of the aforesaid Committees is enclosed herewith as Annexure A.

The Board Meeting commenced at 03:30 P.M. and concluded at 04:45 P.M.

This is for your information and records.

For Concord Biotech Limited

Paritosh Trivedi
Digitally signed by Paritosh Trivedi
Date: 2026.10.27 18:53:05 +05'30'

Paritosh Trivedi
Company Secretary and Compliance Officer
ACS 63623

Limited Review Report on unaudited consolidated financial results of Concord Biotech Limited for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Concord Biotech Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Concord Biotech Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its joint venture for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Limited Review Report (Continued)

Concord Biotech Limited

6. We did not review the interim financial information of two Subsidiaries included in the Statement, whose interim financial information reflects total assets (before consolidation adjustments) of Rs. 316.71 lakhs as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 52.72 lakhs and Rs. 79.58 lakhs, total net profit/(loss) after tax (before consolidation adjustments) of Rs. 0.22 lakhs and Rs. (7.47) lakhs and total comprehensive profit/(loss) (before consolidation adjustments) of Rs. 0.22 lakhs and Rs. (7.47) lakhs, for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively, and cash inflows (net) (before consolidation adjustments) of Rs. 6.55 lakhs for the period from 01 April 2026 to 30 September 2026 as considered in the Statement. These interim financial information have been reviewed by other auditor whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

7. The Statement includes the interim financial information of one Subsidiary which has not been reviewed, whose interim financial information reflects total assets (before consolidation adjustments) of Rs. 1,360.51 lakhs as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 65.65 lakhs and Rs. 73.24 lakhs, total net (loss) after tax (before consolidation adjustments) of Rs. (432.63) lakhs and Rs. (764.36) lakhs and total comprehensive loss (before consolidation adjustments) of Rs. (450.82) lakhs and Rs (781.68) lakhs, for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively, and cash outflows (net) (before consolidation adjustments) of Rs. (279.75) lakhs for the period from 01 April 2026 to 30 September 2026 as considered in the Statement. The Statement also includes the Group's share of net profit after tax (before consolidation adjustments) of Rs. 29.06 lakhs and Rs. 35.32 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 29.06 lakhs and Rs. 35.32 lakhs, for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively as considered in the Statement, in respect of one joint venture, based on its interim financial information which has not been reviewed. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Rupen Dilip
Kumar
Shah

Digitally signed
by Rupen Dilip
Kumar Shah
Date: 2026.10.27
18:58:27 +05'30'

Rupen Shah

Partner

Mumbai

27 October 2026

Membership No.: 116240

UDIN:26116240WJNZHC6030

Limited Review Report (Continued)**Concord Biotech Limited****Annexure I**

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Concord Biotech Limited	Parent Company
2	Concord Lifegen Limited	Wholly owned subsidiary
3	Celliimune Biotech Private Limited	Wholly owned subsidiary
4	Stellon Biotech Inc.	Subsidiary
5	Concord Biotech Japan K.K.	Joint Venture

CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

E-mail : complianceofficer@concordbiotech.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2026

Sr. No.	Particulars	(Rs. In lakhs except per share data)					
		Quarter Ended			Six Month Ended		Year Ended
		30-Sep-26 (Unaudited)	30-Jun-26 (Unaudited)	30-Sep-25 (Unaudited)	30-Sep-26 (Unaudited)	30-Sep-25 (Unaudited)	31-Mar-26 (Audited)
1	Income						
a	Revenue from operations	30,907.02	25,748.90	24,705.75	56,655.92	45,104.51	1,05,489.07
b	Other income	1,016.93	1,282.59	1,335.21	2,299.52	2,702.97	5,235.53
	Total Income	31,923.95	27,031.49	26,040.96	58,955.44	47,807.48	1,10,724.60
2	Expenses						
a	Cost of materials consumed	6,366.30	6,985.45	5,730.43	13,351.75	11,721.41	25,434.78
b	Purchase of stock-in-trade	1,624.47	1,129.00	1,364.51	2,753.47	2,649.14	6,260.63
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(634.88)	(2,685.35)	(2,193.31)	(3,320.22)	(4,958.41)	(7,128.30)
d	Employee benefits expense	5,231.43	4,363.81	4,445.55	9,595.25	8,235.29	17,690.48
e	Finance costs	3.34	3.64	5.91	6.98	11.77	28.32
f	Depreciation and amortisation expense	1,837.68	1,809.95	1,839.15	3,647.63	3,616.78	7,445.86
g	Other expenses						
	Power and fuel	3,663.78	3,472.01	2,852.80	7,135.79	5,800.30	11,619.93
	Others	4,217.91	4,246.40	3,656.66	8,464.31	6,667.98	14,871.56
	Total Expenses	22,310.03	19,324.91	17,701.70	41,634.96	33,744.26	76,223.26
3	Profit before exceptional items and tax (1-2)	9,613.92	7,706.58	8,339.26	17,320.48	14,063.22	34,501.34
4	Exceptional items:						
	Statutory impact of new labour codes (refer note 2)	-	-	-	-	-	327.54
5	Profit before tax and share of profit of joint venture (3-4)	9,613.92	7,706.58	8,339.26	17,320.48	14,063.22	34,173.80
6	Share of profit of joint venture (net of tax)	(65.88)	127.73	229.14	61.85	378.37	290.92
7	Profit before tax (5+6)	9,548.04	7,834.31	8,568.40	17,382.33	14,441.59	34,464.72
8	Tax expenses:						
a	Current tax	2,498.30	2,036.59	2,199.60	4,534.89	3,607.45	8,629.09
b	Deferred tax	92.54	28.03	62.52	120.57	122.07	(87.28)
	Total tax expenses	2,590.84	2,064.62	2,262.12	4,655.46	3,729.52	8,541.81
9	Profit after tax for the period/year (7-8)	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
10	Other comprehensive income (net of tax)						
	Items that will not be reclassified to profit or loss						
a	Re-measurement gain/ (loss) on defined benefit plans	(103.90)	71.56	2.02	(32.34)	(30.05)	(162.24)
b	Income tax relating to re-measurement gain/ (loss) on defined benefit plans	26.15	(18.01)	(0.51)	8.14	7.56	40.83
c	Fair value changes on equity investments through OCI	(892.10)	1,927.33	2,598.15	1,035.23	2,253.54	6,687.09
d	Income tax relating to fair value changes on equity investments through OCI	127.57	(275.61)	(408.99)	(148.04)	(322.26)	(987.87)
e	Items that will be reclassified to profit or loss						
	Foreign currency translation reserves	(18.18)	0.87	(5.49)	(17.31)	(5.49)	(53.45)
	Other comprehensive income for the period/year	(860.46)	1,706.14	2,185.18	845.68	1,903.30	5,524.36
11	Total comprehensive income for the period/year(9+10)	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
12	Profit for the period attributable to:						
	Owners of the company	7,065.35	5,852.62	6,358.09	12,917.96	10,763.88	26,090.59
	Non-controlling interest	(108.15)	(82.93)	(51.81)	(191.09)	(51.81)	(167.68)
	Profit for the period	6,957.20	5,769.69	6,306.28	12,726.87	10,712.07	25,922.91
13	Other comprehensive income for the period attributable to:						
	Owners of the company	(855.93)	1,705.93	2,186.55	850.00	1,904.67	5,537.72
	Non-controlling interest	(4.53)	0.21	(1.37)	(4.32)	(1.37)	(13.36)
	Other comprehensive income for the period	(860.46)	1,706.14	2,185.18	845.68	1,903.30	5,524.36
14	Total comprehensive income for the period attributable to:						
	Owners of the company	6,209.42	7,558.55	8,544.65	13,767.96	12,668.55	31,628.31
	Non-controlling interest	(112.68)	(82.72)	(53.18)	(195.41)	(53.18)	(181.04)
	Total comprehensive income for the period	6,096.74	7,475.83	8,491.46	13,572.55	12,615.37	31,447.27
15	Paid-up equity share capital (face value of Rs. 1/- each)	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
16	Other equity						2,00,659.97
17	Earnings per share						
	Basic and diluted (In Rs.) (not annualised for the quarter)	6.65	5.52	6.03	12.17	10.24	24.78

Refer notes to the unaudited consolidated financial results

CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

E-mail : complianceofficer@concordbiotech.com

Notes to the statement of unaudited consolidated financial results for the quarter and six months ended September 30, 2026 :

1. The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on October 27, 2026. The Statutory Auditors of the holding company have carried out a limited review of the said results.
2. On November 21, 2025, the Government of India notified four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour & Employment notified Central Rules and issued FAQs to enable assessment of the financial impact due to changes in regulations. Based on management's assessment including actuarial valuation, considering the best information available and ICAI guidance, the Group has recognized an incremental liability of ₹ 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under the New Labour Codes. Considering the event as regulatory-driven and non-recurring in nature, the impact of the same has been disclosed under exceptional items in the consolidated results for the year ended March 31, 2026. The Group continues to monitor further clarifications/FAQ from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
3. The Group is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - "Operating Segment".
4. The above consolidated financial results has been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 read together with Companies (Indian Accounting Standards) Rules, 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI").
5. Celliimmune Biotech Private Limited that was incorporated on January 15, 2025 has been acquired by Concord Biotech Limited as on April 02, 2026. Accordingly, Celliimmune Biotech Private Limited is a wholly owned subsidiary from April 02, 2026.
6. The holding company has increased the Authorised Share Capital from ₹ 1,100 lacs, divided into 11,00,00,000 (Eleven Crores) Equity Shares of ₹ 1/- (Rupees One only) each, to ₹ 2,200 lacs, divided into 22,00,00,000 (Twenty-two crores) Equity Shares of ₹ 1/- (Rupees One only) each, by creation of an additional 11,00,00,000 (Eleven Crores) Equity Shares of ₹ 1/- (Rupees One only) each, ranking pari passu in all respects with the existing Equity Shares of the holding company and consequential amendment to Capital Clause of the Memorandum of Association of the holding company, subject to approval of the Shareholders. The holding company has also declared Bonus shares in the proportion of 1:1 i.e. 1 (One) Bonus equity share of ₹ 1/- each for every 1 (One) fully paid-up equity share of ₹ 1/- each held by the Shareholders of the holding company in the Board meeting held on September 23, 2026.

For and on behalf of board of directors of
Concord Biotech Limited

Sudhir
Kumar Vaid

Digitally signed by
Sudhir Kumar Vaid
Date: 2026.10.27
18:52:13 +05'30'

Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

Place: Ahmedabad
Date: October 27, 2026

CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

E-mail : complianceofficer@concordbiotech.com

CONSOLIDATED UNAUDITED STATEMENT OF ASSETS & LIABILITIES

Particulars	(₹ in Lakhs)	
	As at 30 Sep 2026 (Unaudited)	As at 31 March 2026 (Audited)
Assets		
I. Non-current assets		
(a) Property, plant and equipment	75,964.07	78,571.73
(b) Capital work-in-progress	11,164.94	7,815.92
(c) Intangible assets	309.12	25.97
(d) Right-of use assets	163.40	218.07
(e) Goodwill	45.10	39.63
(f) Intangible assets under development	209.46	116.51
(g) Investment accounted for using the equity method	426.41	364.57
(h) Financial assets		
(i) Investments	9,531.29	8,493.72
(ii) Other Financial Assets	1,939.20	646.42
(i) Other non-current assets	2,482.93	1,591.52
(j) Income tax assets (net)	1,027.94	283.81
(k) Deferred tax assets (net)	365.44	293.66
Total non-current assets (A)	1,03,629.30	98,461.53
II. Current assets		
(a) Inventories	39,778.65	32,635.61
(b) Financial assets		
(i) Investments	43,810.01	40,206.37
(ii) Trade receivables	41,249.08	46,019.71
(iii) Cash and cash equivalents	752.27	1,218.60
(iv) Bank balances other than (iii) above	13.19	139.30
(v) Other Financial Assets	1,378.24	2,524.01
(c) Other Current assets	2,086.05	2,267.59
Total current assets (B)	1,29,067.49	1,25,011.18
TOTAL ASSETS (A) + (B)	2,32,696.79	2,23,472.71
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,046.16	1,046.16
(b) Other equity	2,06,529.36	2,00,659.97
Equity attributable to owners of the company	2,07,575.52	2,01,706.13
(c) Non controlling Interest	(387.75)	(192.33)
Total equity (A)	2,07,187.77	2,01,513.80
LIABILITIES		
I. Non-current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	146.51	143.34
(b) Provisions	327.74	371.97
(c) Deferred tax liabilities (net)	4,864.04	4,535.89
Total non-current liabilities (B)	5,338.29	5,051.20
II. Current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	28.45	88.22
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	1,472.98	1,474.95
Total outstanding dues of creditors other than micro enterprises and small enterprises	9,740.33	8,715.99
(iii) Other Financial Liabilities	4,803.07	4,270.41
(b) Provisions	1,243.82	1,123.43
(c) Other current liabilities	2,860.23	1,233.79
(d) Current tax liabilities (net)	21.85	0.92
Total current liabilities (C)	20,170.73	16,907.71
Total Liabilities (D)	25,509.02	21,958.91
TOTAL EQUITY AND LIABILITIES (A) + (D)	2,32,696.79	2,23,472.71

CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

E-mail : complianceofficer@concordbiotech.com

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW

(₹ in Lakhs)

Particulars	For the Six month ended 30 Sep 2026 (Unaudited)	For the Six month ended 30 Sep 2025 (Unaudited)
(A) CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax as per Statement of Profit and Loss	17,382.33	14,441.59
Adjustment for:		
Share of loss/(profit) from joint venture	(61.85)	(378.37)
Depreciation and amortization expenses	3,647.63	3,616.78
Provision for sales return	105.26	50.69
Interest Income	(62.19)	(132.22)
Finance Cost	6.98	11.77
Net gain/loss on termination of lease	(4.47)	-
(Reversal) /Provision for loss allowance	108.09	97.33
Excess provision no longer required written back	(17.89)	(179.84)
(Profit)/loss on sale/discard of Property, plant & equipment	(29.28)	(1.30)
Net gain on sale of investments	(301.85)	(989.75)
Net gain on financial assets measured at fair value through profit or loss	(1,021.44)	(238.01)
Net unrealised foreign exchange (gain) / loss	(277.33)	(690.11)
Operating Profit before Working Capital Changes	19,473.99	15,608.56
Working Capital Changes:		
(Increase) in Inventories	(7,143.04)	(3,661.01)
Decrease in trade receivables	4,912.22	13,079.04
Decrease/(Increase) in other financial assets	1,127.65	(967.66)
Decrease/(Increase) in other assets	192.23	(997.42)
(Decrease) in provisions	(61.45)	(113.98)
Increase/(Decrease) in trade payables	1,145.44	(2,522.03)
Increase in other financial liabilities	877.44	197.66
Increase in other liabilities	1,626.44	673.74
	2,676.93	5,688.34
Cash generated from operations	22,150.92	21,296.90
Direct Taxes paid (Net of Income Tax refund)	(5,329.87)	(6,188.43)
Net cash generated from operating activities	16,821.05	15,108.47
(B) CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, plant & equipment and Intangible Assets (including CWIP and capital advance)	(5,998.57)	(5,349.93)
Proceeds from disposal of Property, plant & equipment	36.08	10.65
Purchase of Current Investments	(42,262.34)	(46,133.26)
Proceeds from sale of Current Investment	39,979.65	47,780.47
Interest received	62.19	132.22
Proceeds from Bank Deposits (Net) (including margin money deposits)	-	1,431.40
Investment in Current deposits with banks (including margin money deposits)	126.11	-
Proceeds from Non current deposits with Bank (including margin money deposits)	(1,274.66)	-
Net cash used in investing activities	(9,331.54)	(2,128.45)
(C) CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of current borrowings	-	(38.11)
Dividend Paid (net of TDS)	(7,898.40)	(11,193.67)
Interest Paid	5.22	-
Principal Payment of Lease Liabilities	(56.60)	(98.16)
Interest paid on Lease Liabilities	(6.06)	(11.72)
Net cash used in financing activities	(7,955.84)	(11,341.66)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A)+(B)+(C)	(466.33)	1,638.36
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	1,218.60	90.45
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	752.27	1,728.81
Cash and cash equivalents comprises of:	As at 30 Sep 2026	As at 30 Sep 2025
Cash on hand	1.99	2.67
Balance with Banks	750.28	1,726.14
Total	752.27	1,728.81

Limited Review Report on unaudited standalone financial results of Concord Biotech Limited for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Concord Biotech Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Concord Biotech Limited (hereinafter referred to as "the Company") for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Rupen Dilip
Kumar Shah
Digitally signed by
Rupen Dilip Kumar
Shah
Date: 2026.10.27
18:58:58 +05'30'

Rupen Shah

Partner

Mumbai

27 October 2026

Membership No.: 116240

UDIN:26116240TRCVOZ9213

CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

E-mail : complianceofficer@concordbiotech.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2026

(Rs. In lakhs except per share data)

Sr. No.	Particulars	Quarter Ended			Six Month Ended		Year Ended
		30-Sept-26 (Unaudited)	30-Jun-26 (Unaudited)	30-Sept-25 (Unaudited)	30-Sep-26 (Unaudited)	30-Sep-25 (Unaudited)	31-Mar-26 (Audited)
1	Income						
a	Revenue from operations	31,231.38	26,051.71	24,705.75	57,283.09	45,104.51	1,05,507.10
b	Other income	1,045.43	1,309.64	1,342.91	2,355.07	2,710.67	5,273.06
	Total Income	32,276.81	27,361.35	26,048.66	59,638.16	47,815.18	1,10,780.16
2	Expenses						
a	Cost of materials consumed	6,366.30	6,985.45	5,730.43	13,351.75	11,721.41	25,434.78
b	Purchase of stock-in-trade	1,569.52	1,125.96	1,364.51	2,695.48	2,649.14	6,222.86
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(365.56)	(2,547.18)	(2,193.31)	(2,912.74)	(4,958.41)	(7,061.49)
d	Employee benefits expense	4,904.10	4,118.15	4,318.27	9,022.26	8,108.01	17,018.60
e	Finance costs	1.49	1.50	5.86	2.99	11.72	23.40
f	Depreciation and amortisation expense	1,833.54	1,804.73	1,838.96	3,638.27	3,616.59	7,432.51
g	Other expenses						
	Power and fuel	3,663.06	3,472.01	2,852.80	7,135.07	5,800.30	11,619.93
	Others	4,112.15	4,179.77	3,579.39	8,291.92	6,590.71	14,618.85
	Total expenses	22,084.60	19,140.39	17,496.91	41,225.00	33,539.47	75,309.44
3	Profit before exceptional items and tax (1-2)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,470.72
4	Exceptional items:						
	Statutory impact of new labour codes (refer note 2)	-	-	-	-	-	327.54
5	Profit before tax (3-4)	10,192.21	8,220.96	8,551.75	18,413.16	14,275.71	35,143.18
6	Tax expenses:						
a	Current tax	2,498.30	2,036.59	2,199.60	4,534.89	3,607.45	8,629.09
b	Deferred tax	122.52	65.00	62.52	187.52	122.07	187.42
	Total tax expenses	2,620.82	2,101.59	2,262.12	4,722.41	3,729.52	8,816.51
7	Profit after tax for the period/year (5-6)	7,571.39	6,119.37	6,289.63	13,690.75	10,546.19	26,326.67
8	Other comprehensive income (net of tax)						
	Items that will not be reclassified to profit or loss						
a	Re-measurement gain/ (loss) on defined benefit plans	(103.91)	71.56	2.02	(32.34)	(30.05)	(162.24)
b	Income tax relating to re-measurement gain/ (loss) on defined benefit plans	26.15	(18.01)	(0.51)	8.14	7.56	40.83
c	Fair value changes on equity investments through OCI	(892.10)	1,927.33	2,598.15	1,035.23	2,253.54	6,687.09
d	Income tax relating to fair value changes on equity investments through OCI	127.57	(275.61)	(408.99)	(148.04)	(322.26)	(987.87)
	Other comprehensive income for the period/year	(842.29)	1,705.27	2,190.67	862.99	1,908.79	5,577.81
9	Total comprehensive income for the period/year (7+8)	6,729.10	7,824.64	8,480.30	14,553.74	12,454.98	31,904.48
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
11	Other equity						2,00,929.01
12	Earnings per share						
	Basic and diluted (In Rs.) (not annualised for the quarter)	7.24	5.85	6.01	13.09	10.08	25.17

Refer notes to the unaudited standalone financial results

CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

E-mail : complianceofficer@concordbiotech.com

Notes to the statement of unaudited standalone financial results for the quarter and six months ended September 30, 2026 :

1. The above standalone financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on October 27, 2026. The Statutory Auditors of the company have carried out a limited review of the said results.
2. On November 21, 2025, the Government of India notified four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour & Employment notified Central Rules and issued FAQs to enable assessment of the financial impact due to changes in regulations. Based on management's assessment including actuarial valuation, considering the best information available and ICAI guidance, the company has recognized an incremental liability of ₹ 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under the New Labour Codes. Considering the event as regulatory-driven and non-recurring in nature, the impact of the same has been disclosed under exceptional items in the consolidated results for the year ended March 31, 2026. The company continues to monitor further clarifications/FAQ from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
3. The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - "Operating Segment".
4. The above standalone financial results has been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 read together with Companies (Indian Accounting Standards) Rules, 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI").
5. Celliimmune Biotech Private Limited that was incorporated on January 15, 2025 has been acquired by Concord Biotech Limited as on April 02, 2026. Accordingly, Celliimmune Biotech Private Limited is a wholly owned subsidiary from April 02, 2026.
6. The Company has increased the Authorised Share Capital of the Company from ₹ 1,100 lacs, divided into 11,00,00,000 (Eleven Crores) Equity Shares of ₹ 1/- (Rupees One only) each, to ₹ 2,200 lacs, divided into 22,00,00,000 (Twenty-two crores) Equity Shares of ₹ 1/- (Rupees One only) each, by creation of an additional 11,00,00,000 (Eleven Crores) Equity Shares of ₹ 1/- (Rupees One only) each, ranking pari passu in all respects with the existing Equity Shares of the Company and consequential amendment to Capital Clause of the Memorandum of Association of the Company, subject to approval of the Shareholders. The company has also declared Bonus shares in the proportion of 1:1 i.e. 1 (One) Bonus equity share of ₹ 1/- each for every 1 (One) fully paid-up equity share of ₹ 1/- each held by the Shareholders of the Company in the Board meeting held on September 23, 2026.

For and on behalf of board of directors of
Concord Biotech Limited

Sudhir

Kumar Vaid

Digitally signed by Sudhir Kumar
Vaid
Date: 2026.10.27 18:52:33 +05'30'

Sudhir Vaid

Chairman & Managing Director

DIN: 00055967

Place: Ahmedabad

Date: October 27, 2026

CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

E-mail : complianceofficer@concordbiotech.com

STANDALONE UNAUDITED STATEMENT OF ASSETS & LIABILITIES

(₹ in Lakhs)

Particulars	As at 30 Sep 2026 (Unaudited)	As at 31 March 2026 (Audited)
Assets		
I. Non-current assets		
(a) Property, plant and equipment	75,956.79	78,563.34
(b) Capital work-in-progress	11,164.94	7,815.92
(c) Intangible assets	307.98	24.58
(d) Right-of use assets	44.60	53.51
(e) Intangible assets under development	139.03	116.51
(f) Financial assets		
(i) Investments	9,666.09	8,562.52
(ii) Other Financial Assets	4,113.87	2,120.45
(g) Other non-current assets	2,449.32	1,591.53
(h) Income tax assets (net)	1,027.94	283.81
Total non-current assets (A)	1,04,870.56	99,132.17
II. Current assets		
(a) Inventories	39,298.44	32,568.80
(b) Financial assets		
(i) Investments	43,810.01	40,206.37
(ii) Trade receivables	41,865.89	46,060.15
(iii) Cash and cash equivalents	594.38	788.89
(iv) Bank balances other than (iii) above	13.19	139.30
(v) Other Financial Assets	1,378.22	2,529.66
(c) Other Current assets	2,031.86	2,228.44
Total current assets (B)	1,28,991.99	1,24,521.61
TOTAL ASSETS (A) + (B)	2,33,862.55	2,23,653.78
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,046.16	1,046.16
(b) Other equity	2,07,584.36	2,00,929.01
Total equity (A)	2,08,630.52	2,01,975.17
LIABILITIES		
I. Non-current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	35.13	45.55
(b) Provisions	327.74	371.97
(c) Deferred tax liabilities (net)	4,864.03	4,536.62
Total non-current liabilities (B)	5,226.90	4,954.14
II. Current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	19.13	17.43
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	1,472.98	1,474.95
Total outstanding dues of creditors other than micro enterprises and small enterprises	9,635.36	8,643.23
(iii) Other Financial Liabilities	4,792.17	4,232.53
(b) Provisions	1,243.82	1,123.43
(c) Other current liabilities	2,819.83	1,231.92
(d) Current tax liabilities (net)	21.84	0.98
Total current liabilities (C)	20,005.13	16,724.47
Total Liabilities (D)	25,232.03	21,678.61
TOTAL EQUITY AND LIABILITIES (A) + (D)	2,33,862.55	2,23,653.78

CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

E-mail : complianceofficer@concordbiotech.com

UNAUDITED STANDALONE STATEMENT OF CASH FLOW

(₹ in Lakhs)

Particulars	For the Six month ended 30 Sep 2026 (Unaudited)	For the Six month ended 30 Sep 2025 (Unaudited)
(A) CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax as per Statement of Profit and Loss	18,413.16	14,275.71
Adjustment for:		
Depreciation and amortization expenses	3,638.27	3,616.59
Provision for sales return	105.26	50.69
Interest Income	(124.29)	(139.92)
Finance Cost	2.99	11.72
(Reversal) /Provision for loss allowance	108.09	97.33
Excess provision no longer required written back	(17.89)	(179.84)
(Profit)/loss on sale/discard of Property, plant & equipment	(29.28)	(1.30)
Net gain on sale of investments	(301.85)	(989.75)
Net gain on financial assets measured at fair value through profit or loss	(1,021.44)	(238.01)
Net unrealised foreign exchange (gain) / loss	(277.33)	(690.11)
Operating Profit before Working Capital Changes	20,495.69	15,813.11
Working Capital Changes:		
(Increase) in Inventories	(6,729.64)	(3,661.01)
Decrease in trade receivables	4,335.85	13,079.04
Decrease/(Increase) in other financial assets	432.68	(1,417.93)
Decrease/(Increase) in other assets	207.28	(996.48)
(Decrease) in provisions	(61.45)	(113.98)
Increase/(Decrease) in trade payables	1,035.71	(2,519.36)
Increase in other financial liabilities	904.42	197.66
Increase in other liabilities	1,587.91	673.62
	1,712.76	5,241.56
Cash generated from operations	22,208.45	21,054.67
Direct Taxes paid (Net of Income Tax refund)	(5,258.16)	(6,188.43)
Net cash generated from operating activities	16,950.29	14,866.24
(B) CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, plant & equipment and Intangible Assets (including CWIP and capital advance)	(5,894.84)	(5,344.34)
Proceeds from disposal of Property, plant & equipment	36.08	10.65
Acquisition of subsidiary , net of cash	(64.80)	(2.28)
Purchase of Current Investments	(42,263.54)	(46,133.26)
Proceeds from sale of Current Investment	39,979.65	47,780.47
Interest received	124.29	139.92
Proceeds from Bank Deposits (Net) (including margin money deposits)	-	1,431.40
Investment in Current deposits with banks (including margin money deposits)	126.11	-
Proceeds from Non current deposits with Bank (including margin money deposits)	(1,274.65)	-
Net cash used in investing activities	(9,231.70)	(2,117.44)
(C) CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of current borrowings	-	(38.11)
Dividend Paid (net of TDS)	(7,898.40)	(11,193.67)
Principal Payment of Lease Liabilities	(11.71)	(98.16)
Interest paid on Lease Liabilities	(2.99)	(11.72)
Net cash used in financing activities	(7,913.10)	(11,341.66)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A)+(B)+(C)	(194.51)	1,407.14
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	788.89	90.45
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	594.38	1,497.59
Cash and cash equivalents comprises of:	As at 30 Sep 2026	As at 30 Sep 2025
Cash on hand	1.98	2.22
Balance with Banks	592.40	1,495.37
Total	594.38	1,497.59

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

Encl : As above

- A. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc. - **Not Applicable**
- B. Format for Disclosing Outstanding Default on Loans and Debt Securities — **Not Applicable, No Default**
- C. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted Along with Annual Audited Financial Results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - **Not Applicable**

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

Annexure – A

Audit Committee		
Sr. No.	Name of Member	Designation
1.	Mr. Arvind Agarwal (Independent Non-Executive Director)	Chairman
2.	Mr. Jayaram Easwaran (Independent Non-Executive Director)	Member
3.	Mr. Ravi Kapoor (Non-Independent Director)	Member

Nomination & Remuneration Committee		
Sr. No.	Name of Member	Designation
1.	Mr. Mandayam Chakravarthy Sriraman (Independent Non-Executive Director)	Chairman
2.	Mr. Arvind Agarwal (Independent Non-Executive Director)	Member
3.	Mrs. Ekta Gupta (Independent Non-Executive Director)	Member

Risk Management Committee		
Sr. No.	Name of Member	Designation
1.	Mr. Ankur Vaid (Executive Director)	Chairman
2.	Mr. Ravi Kapoor (Non-Independent Director)	Member
3.	Mr. Mandayam Chakravarthy Sriraman (Independent Non-Executive Director)	Member

Corporate Social Responsibility Committee		
Sr. No.	Name of Member	Designation
1.	Mr. Ankur Vaid (Executive Director)	Chairman
2.	Mr. Rajiv Agarwal (Non-Independent Director)	Member
3.	Mrs. Ekta Gupta (Independent Non-Executive Director)	Member